Trials / Not Yet Recruiting
Not Yet RecruitingNCT07210554
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stapokibart injection | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2025-11-11
- Primary completion
- 2028-03-27
- Completion
- 2028-05-08
- First posted
- 2025-10-07
- Last updated
- 2025-10-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07210554. Inclusion in this directory is not an endorsement.